Validating a Proteomic Signature of Severe COVID-19
Christopher V. Cosgriff(University of Pennsylvania), Nuala J. Meyer(Translational Therapeutics (United States)), C.A.G. Ittner(University of Pennsylvania), Ariel R. Weisman(University of Pennsylvania), R.S. Agyekum(Translational Therapeutics (United States)), Todd A. Miano(University of Pennsylvania), Divij Mathew(Parker Institute for Cancer Immunotherapy), Brian J. Anderson(University of Pennsylvania), Tiffanie K. Jones(University of Pennsylvania), Nilam S. Mangalmurti(Translational Therapeutics (United States)), E. John Wherry(Parker Institute for Cancer Immunotherapy), Sharon Adamski(United States Military Academy), M. Betina Pampena(University of Pennsylvania), Allison R. Greenplate(California University of Pennsylvania), H.M. Giannini(Lung Institute), Alexander C. Huang(University of Pennsylvania), Leticia Kuri-Cervantes(University of Pennsylvania), Michael O. Harhay(California University of Pennsylvania), Kurt D’Andrea(University of Pennsylvania), John P. Reilly(University of Pennsylvania), Alexandra P. Turner(University of Pennsylvania), Oluwatosin Oniyide(University of Pennsylvania), M.G.S. Shashaty(University of Pennsylvania), Thomas Dunn(Translational Therapeutics (United States)), Michael R. Betts(University of Pennsylvania)
Cited by 9
Related Papers
Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal
|BMJ|2020|3.3k
Lineage relationship and protective immunity of memory CD8 T cell subsets
|Nature Immunology|2003|1.9k
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
|Nature|2010|1.8k
A minimal common outcome measure set for COVID-19 clinical research
|The Lancet Infectious Diseases|2020|1.8k